

## Summary of Product Characteristics

### 1 NAME OF THE MEDICINAL PRODUCT

Diprobath 46% w/w and 39% w/w Bath Additive

### 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Light Liquid Paraffin 46.0% w/w

Isopropyl Myristate 39.0% w/w

For a full list of excipients, see section 6.1

### 3 PHARMACEUTICAL FORM

Bath additive

Clear, colourless, oily liquid

### 4 CLINICAL PARTICULARS

#### 4.1 Therapeutic Indications

For the treatment of dry skin conditions and other hyperkeratoses including those associated with dermatitis and eczema.

#### 4.2 Posology and method of administration

To be applied externally, diluted in a bath of water.

Adults including elderly patients: 25 ml or approximately 2.5 capfuls to be diluted in a bath of water (100:1 approximately). For particularly dry skin, the quantity of oil emollient may be doubled.

10ml or one capful is sufficient for children's bath.

Frequency and duration of bathing will depend on the type and severity of the conditions, but generally 2 to 3 baths should be taken weekly.

#### 4.3 Contraindications

Known sensitivity to any of the ingredients.

#### 4.4 Special warnings and precautions for use

As Diprobath deposits a film of oil over the skin, care should be taken to avoid slipping in the bath. The following warning will appear on the label:

“Take care when entering or leaving the bath which may be more slippery than usual”.

#### 4.5 Interaction with other medicinal products and other forms of interaction

None known.

#### **4.6 Fertility, pregnancy and lactation**

No special precautions.

#### **4.7 Effects on ability to drive and use machines**

Not applicable.

#### **4.8 Undesirable effects**

None known.

#### **4.9 Overdose**

Not applicable.

### **5 PHARMACOLOGICAL PROPERTIES**

#### **5.1 Pharmacodynamic properties**

Light liquid paraffin and Isopropyl Myristate are known emollients and their combination in Diprobath provides a suitable bathing additive to reduce moisture loss.

#### **5.2 Pharmacokinetic properties**

Pharmacokinetic principles are not involved due to direct topical application.

#### **5.3 Preclinical safety data**

Not relevant.

### **6 PHARMACEUTICAL PARTICULARS**

#### **6.1 List of excipients**

Laureth - 4  
(lauromacrogol)

#### **6.2 Incompatibilities**

Not applicable.

#### **6.3 Shelf life**

2 years.

#### **6.4 Special precautions for storage**

Do not store above 25°C.

## **6.5 Nature and contents of container**

500 ml: natural opaque high-density polyethylene (HDPE) single neck bottle with a polypropylene screw cap. Mounted in the cap is a polyethylene liner containing a polytetrafluoroethylene (PTFE) venting disc.

## **6.6 Special precautions for disposal of a used medicinal product or waste materials derived from such medicinal product and other handling of the product**

No special requirements.

## **7 MARKETING AUTHORISATION HOLDER**

Merck Sharp & Dohme Ireland (Human Health) Limited  
Red Oak North  
South County Business Park  
Leopardstown  
Dublin 18  
Ireland

## **8 MARKETING AUTHORISATION NUMBER**

PA 1286/36/1

## **9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 14 March 1995

Date of last renewal: 01 January 2007

## **10 DATE OF REVISION OF THE TEXT**

April 2014